Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging

Felix Eckstein, Wolfgang Wirth, Ali Guermazi, Susanne Maschek, Aida Aydemir, Felix Eckstein, Wolfgang Wirth, Ali Guermazi, Susanne Maschek, Aida Aydemir

Abstract

Objective: To determine whether an anabolic drug (sprifermin) is capable of reducing cartilage loss wherever it occurs in a given knee, using a subject-specific, location-independent analysis of cartilage change in patients with knee osteoarthritis (OA).

Methods: Study participants (n = 168; ages ≥40 years, 69% women) had symptomatic femorotibial OA not confined to the medial compartment. Sprifermin (10, 30, or 100 μg) or placebo was injected intraarticularly 3 times over 3 weeks, both after randomization (baseline) and 3 months later. Coronal magnetic resonance images were acquired at baseline and 3, 6, and 12 months after treatment. The femorotibial cartilage of each subject was segmented, and changes in cartilage thickness were computed across 16 subregions. Location-independent post hoc analysis was used to compute summary scores of negative and positive changes in the subregions, summarized as the total cartilage thinning sum score (ThCTnS) and the total cartilage thickening sum score (ThCTkS), capturing change in either direction in each knee. Ordered values of the magnitude of subject-specific subregional changes in thickness were determined. The ThCTnS and ThCTkS in each sprifermin dose group at 12 months of followup were compared with the values in the matched placebo groups, using the Wilcoxon-Mann-Whitney test.

Results: The mean ± SD ThCTnS was -591 ± 617 μm (median -360 μm, Q1/Q3 = -820/-200 μm) in patients treated with 100 μg sprifermin (n = 57), and -921 ± 777 μm (median -745 μm, Q1/Q3 = -1,190/-380 μm) in patients given placebo (n = 18). The mean difference in the ThCTnS between the 100-μg sprifermin group and the placebo group was 331 μm (95% confidence interval [95% CI] 24, 685), a difference that was statistically significant (P = 0.03). The mean difference in the ThCTkS in the 100-μg sprifermin group compared with the placebo group was 237 μm (95% CI 34, 440), also a statistically significant difference (P = 0.028).

Conclusion: Sprifermin not only increases cartilage thickness, but also reduces cartilage loss. Subject-specific, location-independent analysis of both cartilage thinning and thickening represents a sensitive and informative approach for studying the effects of disease-modifying OA drugs.

Trial registration: ClinicalTrials.gov NCT01033994.

© 2015, American College of Rheumatology.

Figures

Figure 1
Figure 1
Change from baseline in subregional cartilage thickness at 12 months of followup, according to A, subregions of the cartilage and B, ordered values (OVs) of the magnitude of change in cartilage thickness (ranging from OV1, representing greatest cartilage loss, to OV16, representing greatest cartilage thickening). Significant treatment effects (unadjusted P < 0.05) were detected in 4 of 16 subregions and in 10 of 16 OVs. Bars show the mean and 95% confidence interval (95% CI). Symbols indicate individual change values that differed significantly between the 100 μg sprifermin–treated and placebo‐treated patients. MT = medial tibia; cMF = central part of the medial weight‐bearing femur; LT = lateral tibia; cLF = central part of the lateral weight‐bearing femur.

References

    1. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken) 2013;65:703–11.
    1. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.
    1. Weinstein AM, Rome BN, Reichmann WM, Collins JE, Burbine SA, Thornhill TS, et al. Estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am 2013;95:385–92.
    1. Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double‐blind, randomised placebo‐controlled trial. Ann Rheum Dis 2013;72:179–86.
    1. Hellio Le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, et al. A 2‐year randomised, double‐blind, placebo‐controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD‐6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013;72:187–95.
    1. Eckstein F, Guermazi A, Gold G, Duryea J, Hellio Le Graverand MP, Wirth W, et al. Imaging of cartilage and bone: promises and pitfalls in clinical trials of osteoarthritis. Osteoarthritis Cartilage 2014;22:1516–32.
    1. Raynauld JP, Martel‐Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al. Protective effects of licofelone, a 5‐lipoxygenase and cyclo‐oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009;68:938–47.
    1. Wildi LM, Raynauld JP, Martel‐Pelletier J, Beaulieu A, Bessette L, Morin F, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double‐blind, placebo‐controlled pilot study using MRI. Ann Rheum Dis 2011;70:982–89.
    1. Pelletier JP, Roubille C, Raynauld JP, Abram F, Dorais M, Delorme P, et al. Disease‐modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis 2015;74:422–9.
    1. Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: randomized, double‐blind, placebo‐controlled trial. Arthritis Rheumatol 2014;66:1820–31.
    1. Buck RJ, Wirth W, Dreher D, Nevitt M, Eckstein F. Frequency and spatial distribution of cartilage thickness change in knee osteoarthritis and its relation to clinical and radiographic covariates: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2013;21:102–9.
    1. Chang A, Moisio K, Chmiel JS, Eckstein F, Guermazi A, Almagor O, et al. Subregional effects of meniscal tears on cartilage loss over 2 years in knee osteoarthritis. Ann Rheum Dis 2011;70:74–9.
    1. Wirth W, Eckstein F. A technique for regional analysis of femorotibial cartilage thickness based on quantitative magnetic resonance imaging. IEEE Trans Med Imaging 2008;27:737–44.
    1. Wirth W, Buck R, Nevitt M, Le Graverand MP, Benichou O, Dreher D et al. MRI‐based extended ordered values more efficiently differentiate cartilage loss in knees with and without joint space narrowing than region‐specific approaches using MRI or radiography: data from the OA Initiative. Osteoarthritis Cartilage 2011;19:689–99.
    1. Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B et al. Fibroblast growth factor‐18 stimulates chondrogenesis and cartilage repair in a rat model of injury‐induced osteoarthritis. Osteoarthritis Cartilage 2005;13:623–31.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi